Related references
Note: Only part of the references are listed.A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
V. A. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets
Dae Ho Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial
R. Rosell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
F. F. Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
Kyoichi Kaira et al.
LUNG CANCER (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status
Glenwood Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
Tony S. K. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
Cesare Gridelli et al.
ONCOLOGIST (2009)
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Southwest oncology group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
Paul J. Hesketh et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
Giuseppe Giaccone et al.
CLINICAL CANCER RESEARCH (2006)
First line chemotherapy in advanced or metastatic NSCLC
M. Rinaldi et al.
ANNALS OF ONCOLOGY (2006)
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
S Niho et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical features of 5,628 primary lung cancer patients - Experience at Mayo clinic from 1997 to 2003
P Yang et al.
CHEST (2005)
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer
TA Hensing et al.
LUNG CANCER (2005)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models
B Higgins et al.
ANTI-CANCER DRUGS (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment
N Normanno et al.
ENDOCRINE-RELATED CANCER (2003)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)